Renal Cancer - Results from #360

Identification of a lactate metabolism-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma. May 13, 2024

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials. May 13, 2024

Comparison of the perioperative outcomes of robot-assisted laparoscopic transperitoneal versus retraperitoneal partial nephrectomy for posterior-lateral renal tumors: a systematic review and meta-analysis. May 10, 2024

Can 18F FDG PET/CT metabolic parameters be used to noninvasively differentiate between different histopathological subtypes and Fuhrman grades of renal cell cancer? May 10, 2024

Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data. May 9, 2024

Clinical and pathological characteristics of renal cell carcinomas with MiTF translocation. May 9, 2024

Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology. May 8, 2024

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes. May 8, 2024

Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study). May 7, 2024

Clinical Implications of a Six-Protein Signature in Bone Metastasis of Renal Cell Carcinoma. May 7, 2024

High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. May 6, 2024

Development and validation of a multicenter Cox regression model to predict all-cause mortality in patients with renal masses suspicious for renal cancer. May 6, 2024

Disparities in Trend of Renal Cell Carcinoma Mortality in the United States. May 6, 2024

Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region. May 6, 2024

Geographic variation of mutagenic exposures in kidney cancer genomes. May 3, 2024

Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial. May 3, 2024

Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal. May 2, 2024

Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. May 2, 2024

Comparing Perioperative Complications of Off-Clamp versus On-Clamp Partial Nephrectomy for Renal Cancer Using a Novel Energy Balancing Weights Method. May 1, 2024

Molecular subtypes as potential biomarkers in renal cell carcinoma. May 1, 2024

Page 19 of 456